TheraRadar
Data updated: May 26, 2026

ZENPEP (pancrelipase (amylase)

Gastrointestinal Approved 2009-08-27

ZENPEP is indicated for the treatment of Exocrine Pancreatic Insufficiency.

Source: FDA Label • EURAND PHARMA LTD

How ZENPEP Works

ZENPEP contains a mixture of lipases, proteases, and amylases that mimic the physiological activity of natural pancreatic enzymes. These enzymes catalyze the hydrolysis of fats into fatty acids, proteins into peptides and amino acids, and starches into dextrins and short-chain sugars. This process occurs within the duodenum and proximal small intestine to facilitate the breakdown of nutrients for digestion.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
16
Years on Market

Details

Status
Prescription
First Approved
2009-08-27
Routes
ORAL
Dosage Forms
CAPSULE, DELAYED RELEASE

Companies

Active Ingredient: PANCRELIPASE (AMYLASE , LIPASE , PROTEASE)

ZENPEP Approval History

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
112 FDA actions from 2009 to 2024
Feb 2024 SUPPL
Label · Labeling
Oct 2023 SUPPL
Label · Labeling
Sep 2022 SUPPL
Label · Labeling

What ZENPEP Treats

1 indications

ZENPEP is approved for 1 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Exocrine Pancreatic Insufficiency
Source: FDA Label

ZENPEP Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

1

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ZENPEP

3 of 4

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CREON
PANCRELIPASE (AMYLASE
1 shared
AbbVie
Shared indications:
Exocrine Pancreatic Insufficiency
PANCREAZE
PANCRELIPASE (AMYLASE
1 shared
VIVUS INC
Shared indications:
Exocrine Pancreatic Insufficiency
PERTZYE
PANCRELIPASE (AMYLASE
1 shared
DIGESTIVE CARE INC
Shared indications:
Exocrine Pancreatic Insufficiency
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01159119 EUR-1066 PR-012 Ph 1 terminated A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZENPEP FDA Label Details

Indications & Usage

FDA Label (PDF)

ZENPEP is indicated for the treatment of Exocrine Pancreatic Insufficiency.

Track ZENPEP with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.